In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda/ Millennium: The Price is Right

Executive Summary

Takeda and Millennium's recent out-sized tie-up reflects the different but real industry pressures from which both companies are suffering.Facing near-term patent exiprations of several key drugs, Takeda desperately needed to bulk up its R&D pipeline. Millennium, for its own part, was heavily dependent on the label expansion of its lead product, Velcade, as it struggled to maintain sustainable earnings growth and advance its early stage compounds through the clinic.

You may also be interested in...



Takeda Emerging Market Strategy Varies From Country To Country: An Interview With PharmAsia News

Takeda’s expansion into emerging markets using its Nycomed acquisition has positioned it well in Russia and Brazil and given Japan’s largest drug maker a small but solid base in China. But its head of international operations says he’s in no rush to expand into India, given the fluid and complex nature of that market.

Takeda Emerging Market Strategy Varies From Country To Country

Takeda’s expansion into emerging markets using its Nycomed acquisition have positioned it well in Russia and Brazil and given Japan’s largest drug maker a small but solid base in China, but its head of international operations says he’s in no rush to expand into India, given the fluid and complex nature of that market.

Biogen Makes Counterintuitive Move To Tap Exelixis's Scangos As CEO

Shortly after the market closed on June 30, Biogen Idec and Exelixis confirmed leadership changes that will result in Exelixis's long-time CEO George Scangos taking the helm of the Big Biotech July 15

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1132082

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel